From a clinical perspective, our data, and those of others19, 20, suggest that therapeutic targeting of CCR6 will have detrimental effects on Treg function without restraining pathogenic T cells and emphasize CCR2 as a prospective target for the treatment of inflammatory T-cell-driven pathologies such as MS. The gene discussed is CCR2; the disease is myeloid sarcoma.